#USA #Chicago #Veterans #Lenire #Hearoes Tour

Lenire Supporting Veterans through the Hearoes Tour

Lenire, known for its groundbreaking FDA-approved tinnitus treatment device, is taking a stand to support veterans by sponsoring the 10th Annual Hearoes Tour organized by the LexCare Hearing Foundation. This initiative is pivotal in raising awareness about the need for better access to hearing and tinnitus care among U.S. veterans, a segment of the population estimated to be living with tinnitus.

The Hearoes Tour operates on a national scale, providing vital resources like free hearing screenings and health education to veteran communities across the United States. With approximately 200 events held yearly, the tour is dedicated to breaking down barriers related to accessibility and affordability for hearing and tinnitus care, while also emphasizing the long-term consequences of untreated hearing loss.

Jaime Motes, the Founder and Director of the LexCare Hearing Foundation, highlighted the importance of the Hearoes Tour, stating that nearly 40% of veterans they serve are affected by tinnitus. For these individuals, effective treatment options have been historically limited. "It's personal for me," Motes shared, referencing her daughter’s journey with cochlear implants. Motes expressed, "Every veteran deserves an answer too. Now, we finally do, thanks to our partnership with Lenire."

The collaboration signifies a milestone in the ongoing mission to destigmatize and improve access to care for veterans suffering from tinnitus. Tinnitus, recognized as the number one service-connected disability by the U.S. Department of Veterans Affairs (VA), has resulted in billions of dollars in service-connected compensation. In 2024 alone, veterans received an astonishing $6.6 billion in such compensation related to tinnitus, which accounted for an impressive 63% of all auditory compensation claims.

Lenire's innovative approach to tinnitus treatment utilizes a bimodal neuromodulation device, effectively combining auditory stimulation with gentle electrical pulses delivered through a unique intra-oral component. This dual-action method has been shown to elicit significant therapeutic outcomes, offering hope to the 3.2 million veterans affected by this debilitating condition.

Currently, 50 facilities within the U.S. Department of Veterans Affairs have been trained to provide Lenire treatment, a number that is anticipated to grow throughout 2025, increasing accessibility to this life-changing therapy. Eric Timm, CEO of Neuromod USA, also voiced optimism about this partnership, outlining its potential impact in facilitating awareness and improving access to tinnitus care for veterans.

Initial results from independent clinics indicate that the device has yielded positive outcomes, with a study conducted at the Alaska Hearing and Tinnitus Center revealing that over 91.5% of 220 participants experienced significant improvement in their tinnitus symptoms after treatment. This evidence supports Lenire’s efficacy and illustrates a promising future for tinnitus therapy, especially among veterans.

Neuromod, established in Dublin, Ireland in 2010, focuses on addressing the needs of patients suffering from various chronic conditions through innovative neuromodulation technologies. Their commitment to aiding veterans aligns seamlessly with their goal to provide effective, accessible treatment options to underserved populations.

As Lenire embarks on this partnership journey with the Hearoes Tour, the hope remains to not only alleviate the suffering of veterans but also foster a greater understanding of tinnitus and its implications. By providing real, actionable solutions, Lenire and the LexCare Hearing Foundation are changing the narrative around tinnitus care for those who have sacrificed so much for their country.

For more information on the Hearoes Tour, visit LexCare Hearing Foundation.

For details on Lenire’s treatment methodologies, access Lenire.